GRACE :: Pancreatic Cancer

Targeted Therapies for Pancreatic Cancer

Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer

Share

Phase I/II Gemcitabine and AbraxaneDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.

 

Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer Audio Podcast


Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer

Share

Gemcitabine Registration StudyDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.

 

Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer Audio Podcast


Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer

Share

Adjuvant TherapyDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.

 

Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer Audio Podcast


Advanced Pancreatic Cancer: Changing Landscape Signals Hope

Share

Pancreatic cancer, though relatively uncommon, is the fourth most common of cancer-related deaths. In the United States, 44,030 new cases of pancreatic cancer were diagnosed with 37,660 deaths in 2011. The average estimated five-year survival of a pancreatic cancer patient with advanced stage of the cancer is 5% or less. Despite these grim figures, a number of recent developments in basic and clinical research offer hope for the future.

Patients with advanced pancreatic cancer include those with cancer spread to liver or other distant organs. In these cases, surgery or radiations are not feasible and chemotherapy remains the sole treatment option. For the past ten years, gemcitabine chemotherapy has been the mainstay for patients with advanced, stage IV pancreatic cancer. The approval of gemcitabine by the F.D.A. was based on an improved survival over the previous standard, 5-fluorouracil chemotherapy. Gemcitabine also led to a ‘clinical benefit response’, or an improvement in pain, appetite, weight and quality of life. In the past decade, there have been several clinical trials, which combined gemcitabine chemotherapy with other chemotherapy agents used in pancreatic cancer. All of these trials indicated that when gemcitabine was combined with another chemotherapy agent (gemcitabine + drug X), the resultant survival was no better than with gemcitabine alone.

Continue reading


Ask Us, Q&A
Pancreatic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243